LH

Business Context and Reporting Period

Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: LabCorp operates as a national reference laboratory providing diagnostic, prognostic, and predictive testing services. The reporting period was significantly impacted by the integration of two major acquisitions (US Pathology Labs and Esoterix) and operational disruptions caused by Hurricanes Katrina and Rita in the Gulf Coast region.

Key Financial Metrics

Note: Total Debt includes $541.7M in current zero-coupon subordinated notes, $353.1M in senior notes, and minor long-term debt/leases.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9.1% ($71.4M) for the quarter and 8.1% ($187.0M) for the nine-month period compared to 2004. Growth was driven by a 2.1% volume increase (quarterly) and 7.0% price increase, aided by the acquisitions of US Pathology Labs and Esoterix.
• Acquisition Impact: The company acquired US Pathology Labs (Feb 2005, ~$155M) and Esoterix (May 2005, ~$150M). These acquisitions contributed significantly to volume growth in genomic and esoteric testing.
• Special Charges: A $10.0M charge was recorded in Q3 2005. This comprised $8.8M for integration costs (severance for ~500 employees and facility leases) and $1.2M for bad debt forgiveness related to Hurricane Katrina and Rita impacts.
• Liquidity Shift: Cash and cash equivalents decreased from $186.8M at year-end 2004 to $52.5M at Sept 30, 2005. This reduction was due to $335.3M in acquisition costs, $201.7M in stock repurchases, and increased capital expenditures ($71.4M).
• Debt Structure: Zero-coupon subordinated notes of $541.7M were reclassified from long-term to current liabilities as they approach a potential redemption date in 2006.

Guidance, Outlook, and Risks

• Outlook: Management estimates Q4 2005 revenues will be negatively impacted by approximately $7.5M (approx. 1% volume decline) due to the continued closure of facilities in southern Mississippi and New Orleans following the hurricanes.
• Capital Expenditures: Total 2005 capital expenditures are expected to be between $90.0M and $100.0M, funded by operating cash flows.
• Stock Repurchases: The company completed a $250M repurchase program in H1 2005 and initiated a new $250M program in April 2005. As of Sept 30, 2005, $171.3M remained available under the new program.
• Legal Contingencies:
  • Shareholder Litigation: Consolidated class action alleging securities fraud regarding 2002 disclosures; defendants deny liability.
  • Patent Litigation: The Supreme Court granted certiorari regarding a patent infringement case (Metabolite Laboratories). The case is expected to be argued by April 2006. A prior judgment of $7.8M has been paid.
  • Regulatory: Ongoing risks related to False Claims Act (qui tam) suits and Medicare/Medicaid billing audits.
• Accounting Changes: The company is evaluating the impact of SFAS No. 123(R) regarding share-based payment, with full impact expected to be disclosed in Q4 2005 results.

Investor Verification Checklist

• Acquisition Integration: Verify the timeline and cost realization of integrating US Pathology Labs and Esoterix, specifically regarding the $8.8M restructuring charge.
• Hurricane Impact Duration: Monitor the operational status of Gulf Coast facilities to assess if the projected $7.5M Q4 revenue impact is accurate or if the disruption extends into 2006.
• Debt Maturity: Review the company's liquidity plan for the $541.7M zero-coupon subordinated notes, which may be put to the company in September 2006.
• Legal Exposure: Track the Supreme Court ruling on the Metabolite patent case, as an adverse outcome could set a precedent affecting future patent enforcement or liability.
• Stock-Based Compensation: Review the Q4 2005 filing for the quantified impact of adopting SFAS 123(R), which may reduce reported net income.